drugset / Trial / NCT00742638

To Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder.

NCT00742638

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, randomised, parallel-group study to compare the efficacy and safety of quetiapine and valproate used as monotherapy in the treatment of mania in patients hospitalised for an acute manic episode. After given of informed consent and undergoing screening procedures, the patients will be randomised into quetiapine or valproate group on Day 1. The efficacy of study treatment on symptoms of mania will be assessed at Day 28. Patients will not permitted to use any psychoactive or antipsychotic medications throughout the study period other than those expressly permitted by the protocol. At each centre, the same individual will administer a specific psychiatric assessment for a patient at all study visits in order to reduce variability in rating scale scoring. Before the initiation of the study, a consistency assessment will be done among the investigators who conduct the scale assessment in each centre.

Timeline

Start
2008-03
Primary completion
2010-05
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 25 mg
Subject Quetiapine Small molecule 200 mg
Comparator Valproate Small molecule 200 mg

Indications